# Elicio Therapeutics Inc. (ELTX)

Source: https://www.quantisnow.com/company/ELTX
Generated: 2026-11-17T22:47:14.740Z

- Ticker: ELTX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- SEC CIK: 0001601485

## Latest ELTX news and filings

- 2026-11-13 21:03 UTC [SEC Form 8-K] [Elicio Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/elicio-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6790414)
- 2026-11-05 21:14 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Elicio Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-elicio-therapeutics-inc-6776656)
- 2026-11-05 21:12 UTC [SEC Form 8-K] [Elicio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/elicio-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6776540)
- 2026-11-05 21:01 UTC [Earnings] [Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/elicio-therapeutics-reports-third-quarter-2026-financial-results-and-provides-6775889)
- 2026-11-04 13:00 UTC [Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC](https://www.quantisnow.com/insight/elicio-therapeutics-to-host-virtual-kol-event-on-november-11-6771424)
- 2026-10-29 13:00 UTC [Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting](https://www.quantisnow.com/insight/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-6762887)
- 2026-10-23 13:00 UTC [Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine](https://www.quantisnow.com/insight/elicio-therapeutics-presents-late-breaking-phase-2-amplify-7p-results-at-esmo-6755963)
- 2026-10-09 20:05 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Elicio Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-elicio-therapeutics-inc-6742870)
- 2026-09-24 12:00 UTC [Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026](https://www.quantisnow.com/insight/elicio-therapeutics-announces-late-breaking-phase-2-amplify-7p-data-selected-for-6724850)
- 2026-09-14 20:03 UTC [SEC Form 8-K] [Elicio Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events](https://www.quantisnow.com/insight/elicio-therapeutics-inc-filed-sec-form-8-k-shareholder-director-nominations-6714372)
- 2026-09-02 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Adams Julian](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-adams-julian-6703095)
- 2026-09-02 20:04 UTC [SEC Form 4] [SEC Form 4 filed by Director Ashe Carol Gail](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ashe-carol-gail-6703064)
- 2026-09-02 20:04 UTC [SEC Form 4] [SEC Form 4 filed by Director Chudnovsky Yekaterina](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-chudnovsky-yekaterina-6703061)
- 2026-09-02 20:03 UTC [SEC Form 4] [SEC Form 4 filed by Director Nissenson Allen](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-nissenson-allen-6703033)
- 2026-09-02 20:03 UTC [SEC Form 4] [SEC Form 4 filed by Director Ruffolo Robert R](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ruffolo-robert-r-6703030)
- 2026-09-02 20:03 UTC [SEC Form 4] [SEC Form 4 filed by Director Wilson Karen J](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-wilson-karen-j-6703029)
- 2026-09-02 20:02 UTC [SEC Form 4] [SEC Form 4 filed by Director Venkatesan Jay](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-venkatesan-jay-6703023)
- 2026-08-31 12:00 UTC [Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/elicio-therapeutics-to-participate-at-the-hc-wainwright-28th-annual-6699128)
- 2026-08-24 12:00 UTC [Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference](https://www.quantisnow.com/insight/elicio-therapeutics-to-participate-at-the-wells-fargo-21st-annual-6692119)
- 2026-08-13 20:08 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Elicio Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-elicio-therapeutics-inc-6680399)
- 2026-08-13 20:06 UTC [SEC Form 8-K] [Elicio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/elicio-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6680345)
- 2026-08-13 20:01 UTC [Public Offering] [Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates](https://www.quantisnow.com/insight/elicio-therapeutics-reports-second-quarter-2026-financial-results-and-provides-6680108)
- 2026-08-10 12:00 UTC [Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma](https://www.quantisnow.com/insight/elicio-therapeutics-announces-activation-of-the-investigator-initiated-phase-1-study-6672807)
- 2026-07-17 20:14 UTC [SEC Form 4] [SEC Form 4 filed by Officer Haqq Christopher](https://www.quantisnow.com/insight/sec-form-4-filed-by-officer-haqq-christopher-6641049)
- 2026-07-17 20:14 UTC [SEC Form 4] [SEC Form 4 filed by Chief Scientific Officer Demuth Peter](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-scientific-officer-demuth-peter-6641047)
- 2026-07-17 20:13 UTC [SEC Form 4] [SEC Form 4 filed by CEO, President and Director Connelly Robert](https://www.quantisnow.com/insight/sec-form-4-filed-by-ceo-president-and-director-connelly-6641045)
- 2026-07-17 20:13 UTC [SEC Form 4] [SEC Form 4 filed by Officer Shah Preetam](https://www.quantisnow.com/insight/sec-form-4-filed-by-officer-shah-preetam-6641044)
- 2026-07-08 18:18 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Elicio Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-elicio-therapeutics-inc-6631385)
- 2026-07-06 20:05 UTC [Public Offering] [Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering](https://www.quantisnow.com/insight/elicio-therapeutics-announces-closing-of-15-million-registered-direct-offering-6628011)
- 2026-07-02 12:16 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Elicio Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-elicio-therapeutics-inc-6624302)
- 2026-07-02 10:20 UTC [SEC Form 8-K] [Elicio Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/elicio-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6624093)
- 2026-07-02 04:25 UTC [Public Offering] [Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering](https://www.quantisnow.com/insight/elicio-therapeutics-announces-pricing-of-15-million-registered-direct-offering-6623968)
- 2026-06-29 12:00 UTC [Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes](https://www.quantisnow.com/insight/elicio-therapeutics-added-to-russell-2000-and-russell-3000-indexes-6618294)
- 2026-06-24 20:05 UTC [SEC Form 8-K] [Elicio Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/elicio-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6614154)
- 2026-06-18 13:23 UTC [Analyst Coverage Resumed] [Ladenburg Thalmann resumed coverage on Elicio Therapeutics with a new price target](https://www.quantisnow.com/insight/ladenburg-thalmann-resumed-coverage-on-elicio-therapeutics-with-a-new-6608178)
- 2026-06-17 12:03 UTC [SEC Form 8-K] [Elicio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/elicio-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6605918)
- 2026-06-17 12:00 UTC [Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer](https://www.quantisnow.com/insight/elicio-therapeutics-reports-multiple-complete-responses-after-eli-002-7p-treatment-6605888)
- 2026-06-15 13:21 UTC [SEC Form 8-K] [Elicio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/elicio-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6602130)
- 2026-06-15 11:00 UTC [Earnings Date] [Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer](https://www.quantisnow.com/insight/elicio-therapeutics-reports-results-from-phase-2-amplify-7p-study-and-6601733)
- 2026-06-10 12:30 UTC [Analyst Coverage Initiated] [B. Riley Securities initiated coverage on Elicio Therapeutics with a new price target](https://www.quantisnow.com/insight/b-riley-securities-initiated-coverage-on-elicio-therapeutics-with-a-6596528)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ELTX
- Earnings history: https://www.quantisnow.com/earnings/ELTX
- Dividend history: https://www.quantisnow.com/dividends/ELTX
- Insider transactions: https://www.quantisnow.com/insiders/ELTX
- Options chain: https://www.quantisnow.com/options/ELTX
- SEC 8-K filings only: https://www.quantisnow.com/company/ELTX/8-k
- RSS and alerts for ELTX: https://www.quantisnow.com/docs/rss-feeds.md
